Year: 2012
Type: article
Study design: Observational Study
Abstract: Unrelated cord blood transplantation (CBT) is not widely used to treat hemoglobinopathies (HGB) despite being the fastest growing stem cell source for unrelated hematopoietic cell transplantation (HCT). Published series show unfavorable disease-free survival (Ruggeri et al. BBMT 2011) or were single institution efforts (Jaing et al. BMT 2011). We analyzed the clinical outcome for 101 HGB patients following CBT. The combination approach to optimize nucleated cell (NC) dose of choosing CB products manufactured by plasma depletion/reduction to maximize NC recovery, double grafts (whenever single CB had insufficient NC dose), and post-thaw direct infusion were used by the 5 Asian transplant centers (TCs) in this series that performed most of the CBT.
Authors: R.Y. Chow, T.-H. Jaing, L.L. Chan, P. Tan, H.-P. Lin, M. Graham, J. Rosenthal, C. Karanes, A. Nademanee, B.C. Wang, L. Yen, M.R. Chow, T. Dang, J. Kurtzberg, L.D. Petz
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2015668790